Meningioma Pipeline Analysis 2018 – Focusing On Clinical Trials And Results, Drug Profiling, Patents, Collaborations, And Other Recent Developments
- Published : Mar 2020
- Report Code : KSI061611444
- Pages : 114
Offered with this report
Market Data and Estimates in Excel
2 Months of Post Sale Analyst Support
Requirement Specific Customization
Meningioma Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Meningioma Pipeline Analysis report covers 13 drugs currently in different phases of development. Meningioma is the tumor that develops in the layer called meninges which protect the brain and spinal cord. These are the most common form of tumors, slow growing and are mostly benign. When small in size meningioma may not cause any symptoms, however, larger size meningioma increase the pressure inside the skull and causes problems like headache, nausea and vomiting and seizures due to electrical disturbances inside the brain. Most of the meningiomas are treated through surgeries. Radiation therapy may also be used to shrink the tumor, or post-surgery to treat small remainders of tumor or if the patient is too ill to undergo surgery.
The report provides meningiomas treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are AstraZeneca, Boehringer Ingelheim GmBH, Eli Lilly and Company, Lixte Biotechnology Holdings, Inc. and Novocure among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. AstraZeneca
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. BioXcel Corporation
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Boehringer Ingelheim
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Bristol Myers Squibb
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Eli Lilly and Company
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. GlaxoSmithKline
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Johnson & Johnson
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Kite Pharma
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Lixte Biotechnology Holdings, Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Merck Sharp & Dohme Corp.
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Novartis
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Novocure
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Pfizer
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
List of Tables
List of Figures
BioXcel Corporation
Boehringer Ingelheim
Bristol Myers Squibb
Eli Lilly and Company
GlaxoSmithKline
Johnson & Johnson
Kite Pharma
Lixte Biotechnology Holdings, Inc.
Merck Sharp & Dohme Corp.
Novartis
Novocure
Pfizer
Related Reports
| Report Name | Published Month | Get Sample PDF |
|---|---|---|
| Epidermolysis Bullosa Care and Treatment Market Size: 2021 - 2026 | May 2021 | |
| Pipeline Security Market Size & Share: Industry Report, 2021 - 2026 | May 2021 | |
| Hemochromatosis (Iron Overload) Pipeline Analysis 2018 (Q1) | Industry Report | Forecasts till 2024 | Mar 2020 | |
| Merkel Cell Carcinoma Pipeline Analysis 2019 (H1) | Mar 2020 | |
| Eosinophilic Esophagitis Pipeline Analysis 2019 (H1) | Mar 2020 |